S-1: Theriva Biologics Announces Proposed Public Offering of Common Stock and Warrants

Theriva Biologics plans to offer shares of common stock and warrants in a public offering to raise capital for working capital and general corporate purposes.

Summary

• Theriva Biologics, Inc. has filed a registration statement for a proposed public offering.
• The offering includes up to 2,173,913 shares of common stock and accompanying common warrants, or pre-funded warrants in lieu of common stock, to purchase up to 2,173,913 shares of common stock.
• Each share of common stock or pre-funded warrant is being sold together with a common warrant to purchase one share of common stock.
• The assumed public offering price is $3.22 per share of common stock and accompanying common warrant, based on the closing price on September 5, 2024.
• The common warrants will have an exercise price to be determined and will expire five years from the issuance date.
• The company is offering pre-funded warrants to purchasers who would otherwise exceed beneficial ownership limitations.
• A.G.P./Alliance Global Partners is acting as the sole placement agent on a best efforts basis.
• The offering will terminate on a date to be determined, unless the closing occurs earlier or the company decides to terminate the offering.
• The company intends to use the net proceeds for working capital, general corporate purposes, and potentially to invest in or acquire other products, businesses, or technologies.
• Directors and officers have agreed to a 90-day lock-up period after the offering.
• The company's common stock is listed on the NYSE American under the symbol TOVX.
• The company is a smaller reporting company and an emerging growth company, which allows for reduced disclosure obligations.

Sentiment

Score: 5

Explanation: The document is neutral in tone, presenting facts about the offering without expressing strong optimism or pessimism. The risks are clearly outlined, balancing the potential benefits of the capital raise.

Positives

• The offering will provide additional working capital for the company.
• The company has flexibility in using the net proceeds for various corporate purposes.
• The company has engaged a placement agent to assist with the offering.
• The company's stock is listed on the NYSE American.
• The company's directors and officers are subject to a 90-day lock-up period.

Negatives

• The offering is on a best efforts basis, so there is no guarantee that all securities will be sold.
• The actual offering price may be at a discount to the current market price.
• There is no established public trading market for the common warrants and pre-funded warrants.
• The company has broad discretion in the use of the net proceeds.
• The company does not intend to pay dividends on the common stock.
• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received by the company.

Risks

• The company may not use the net proceeds effectively.
• The price of the common stock could fluctuate significantly.
• There is no public market for the common warrants or pre-funded warrants.
• The company may not receive any additional funds upon the exercise of the common warrants or pre-funded warrants.
• Stockholders may experience immediate dilution if the company sells common stock or preferred stock in the future.
• The company may sell fewer than all of the securities offered, which may significantly reduce the amount of proceeds received by the company.

Future Outlook

The company intends to use the net proceeds from this offering primarily for working capital and general corporate purposes, including for research and development. The company may also use a portion of the net proceeds to invest in or acquire other products, businesses or technologies, although there are no commitments or agreements with respect to any such investments or acquisitions as of the date of this prospectus.

Industry Context

The company is operating in the biotechnology industry, which is characterized by high risk and uncertainty. The company faces competition from other companies in the industry, including those with greater financial resources.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention that the company is a smaller reporting company and an emerging growth company, which suggests that it is a relatively small player in the industry.
• Comparable companies in the biotechnology industry include those that are developing therapeutics for cancer and related diseases.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• The company's employees may benefit from the additional working capital.
• Customers may benefit from the company's ability to invest in research and development.
• Suppliers may benefit from the company's increased financial stability.
• Creditors may be impacted by the company's increased debt.

Next Steps

• The company will need to price the securities and enter into securities purchase agreements with investors.
• The company will need to file the prospectus with the SEC.
• The company will need to list the shares of common stock on the NYSE American.
• The company will need to close the offering and deliver the securities to the investors.

Key Dates

Keywords

public offering, common stock, warrants, pre-funded warrants, securities, Theriva Biologics, placement agent, A.G.P./Alliance Global Partners, capital raise, NYSE American, TOVX